Arriving in the field of obesity management, retatrutide presents a distinct strategy. Different from many current medications, retatrutide functions as a twin agonist, at once targeting both GLP peptide-1 (GLP-1) and glucose-dependent insulinotropic substance (GIP) binding sites. The dual stimulation promotes various helpful effects, like better s